FogPharma is a clinical-stage oncology company developing novel peptide therapies, specifically targeting intracellular challenges using stapled peptides technology
FogPharma is a clinical-stage oncology company developing novel peptide therapies, specifically targeting intracellular challenges using stapled peptides technology. Their lead program focuses on colorectal cancer, targeting β-catenin, a pathway involved in over 20% of all cancers.